Key result
This review summarizes the available evidence on anticoagulant and non-anticoagulant treatments for symptomatic venous thromboembolism in patients with active malignancy.
Answers are grounded in this paper and cite their sources.
This review summarizes the available evidence on the treatment of symptomatic VTE in cancer patients, a population at high risk for both recurrence and bleeding.
Venous thromboembolism (VTE) is an important complication in cancer patients, which is associated with bad outcome. Increased recurrence rates and bleeding complications as compared to non-cancer patients during the treatment of VTE, require special attention. This review aims to summarize the available evidence on both the anticoagulant and non-anticoagulant treatment of symptomatic VTE in patients with active malignancy.
No takes yet. Share an insight, caveat, or question.
Sluis et al. (2009) conducted a review in Cancer-Associated Venous Thrombosis. Anticoagulant and non-anticoagulant treatment was evaluated. This review summarizes the available evidence on anticoagulant and non-anticoagulant treatments for symptomatic venous thromboembolism in patients with active malignancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: